ATNM

Actinium Pharmaceuticals, Inc. (ATNM) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies for oncology. The company operates as a single segment and is classified as a non-accelerated filer and a smaller reporting company. As of May 7, 2026, there were 31,374,991 shares of common stock outstanding.

Key Financial Metrics

Note: The company has no commercial revenue. The $35 million deferred revenue relates to an upfront payment from Immedica Pharma AB for the license of Iomab-B in the EUMENA region, pending regulatory approval.

Material Changes vs. Prior Period

• Significant Expense Reduction: Net loss decreased by $10.4 million (65%) compared to Q1 2025. This improvement is primarily driven by a $10.7 million reduction in operating expenses.
• Stock-Based Compensation Impact: Q1 2025 included a one-time $8.7 million non-cash stock-based compensation charge due to the cancellation of 4.9 million stock options. Q1 2026 stock-based compensation was only $11,000.
• Operating Expense Breakdown:
  • R&D Expenses: Decreased from $7.7 million to $4.2 million, driven by lower stock-based compensation ($2.1 million reduction), reduced CRO services, and lower headcount.
  • G&A Expenses: Decreased from $8.9 million to $1.7 million, primarily due to the absence of the $6.6 million stock-based compensation charge from the prior year and reduced consulting/legal fees.
• Liquidity: Cash and cash equivalents decreased by approximately $5.9 million during the quarter, reflecting the net cash burn from operations.

Outlook, Risks, and Management Commentary

• Liquidity Outlook: Management expects existing resources to fund planned operations for more than 12 months following the filing date.
• Pipeline Updates:
  • ATNM-400: Preclinical data presented at AACR 2026 demonstrated pan-tumor efficacy in prostate, lung, and breast cancer models, showing superiority over standard-of-care therapies in resistant settings.
  • Actimab-A: Data supports its role as a backbone therapy for AML and MDS. The company is seeking a strategic partner to execute a Phase 2/3 trial in R/R AML.
  • Iomab-B: The FDA requires an additional randomized head-to-head Phase 3 trial and a dose optimization trial to support a BLA filing, as the previous SIERRA trial data was deemed insufficient. The company is actively seeking a U.S. strategic partner for these trials.
• Legal Proceedings: The company is defending against a putative securities class action lawsuit (In re Actinium Pharmaceuticals, Inc. Securities Litigation) alleging misrepresentations regarding the Iomab-B Phase 3 trial. A motion to dismiss is pending. Derivative litigation is stayed pending the class action resolution.
• Regulatory and Operational Risks:
  • Government Shutdowns: A U.S. federal government shutdown from October 1 to November 12, 2025, curtailed FDA and NIH operations, delaying clinical trials under the company's CRADA with the NCI.
  • Executive Changes: The CFO resigned in February 2026; the CEO, Sandesh Seth, is serving as the Principal Financial Officer.
  • Manufacturing: Construction of a new cGMP radiopharmaceutical manufacturing facility in New York is expected to be operational in H2 2026.

Investor Verification Checklist

• Verify the status of the pending motion to dismiss in the In re Actinium Pharmaceuticals securities class action.
• Confirm the timeline and terms for securing a strategic partner for the FDA-required Iomab-B Phase 2/3 trials.
• Monitor the operational readiness of the new New York manufacturing facility scheduled for H2 2026.
• Assess the impact of the recent government shutdown on the CRADA trials with the National Cancer Institute (NCI).
• Review the company's cash burn rate relative to the stated 12-month liquidity runway.